From:	John Whalan
To:	David Bussard; Bob Sonawane; Gina Perovich; Paul White; Danielle DeVoney; Thomas Bateson; Sury Vulimiri; Jennifer Jinot; Kathleen Raffaele; Susan Makris; Susan Euling; Barbara Glenn; Ravi Subramaniam
Subject:	NAS Public Meeting for Formaldehyde
Date:	07/08/2010 04:06 PM
Attachments:	Public Agenda Meeting 2.doc

I spoke with Ellen Mantus (NAS) this morning. She told me several things that are not covered in her attached Email. The FA panel held a teleconference on Tuesday, July 6. A major outcome of that discussion was that the panel requested an opportunity to interact with some of the formaldehyde team in the morning session (probably 10-noon) of the Monday, August 9 meeting. The panel would like to interact with those who drafted text (i.e., team members) to describe how we reached our conclusions for 3 health effects--asthma, reproduction, and neuro--including how and why we decided to include/exclude individual studies in our RfC derivation. Ellen mentioned only these three areas, but we should be prepared to also discuss closely related areas such as developmental effects and pulmonary function. Ellen said the guidance documents that we use are not helpful in showing how we came to our conclusions. What they seek is a better understanding of our thought processes so they can provide us with a fair and balanced review. NCEA management is, of course, welcome to attend this meeting, but the panel wants to hear from the team members and to keep ppt slides to a minimum (if at all).

John E. Whalan
Toxicologist, ORD-NCEA-IRIS N-7218
Phone: 703-347-8639 FAX: 703-347-8689

US EPA, Mailcode 8601P
1200 Pennsylvania Ave., NW
Washington, DC 20460-0001

Physical location & FedEx:
Two Potomac Yard, Suite N-7218
2733 S. Crystal Drive, Arlington, VA 22202

-----Forwarded by John Whalan/DC/USEPA/US on 07/08/2010 03:37PM -----

To: John Whalan/DC/USEPA/US@EPA
From: "Mantus, Ellen" <EMantus@nas.edu>
Date: 07/08/2010 09:51AM
Subject: Public Meeting

Hi John,

As discussed this morning, the committee would like to have EPA participate in a public meeting on Monday, August 9th, from 10 a.m. to noon to discuss various aspects of the draft assessment. What the committee would like is to have EPA present its decision-making process for the following end points: asthma, reproductive toxicity, and neurotoxicity. The committee does not want a detailed description of each study, but a discussion on moving from the body of studies to the actual conclusion made. For example, why certain studies were identified as key studies; what study attributes made it a key study? Or why other studies were not carried forward or used. EPA should view this request as a presentation of three case studies in its decision-making process. As we discussed, I think it would be best to limit the PowerPoints and think of this as a more informal venue, although it will be a public session. Please let me know if you have any questions, and please confirm your participation. I need to post an agenda soon (see attached). Thanks.

Ellen

Ellen
K. Mantus, Ph.D.

Senior
Program Officer

Board
on Environmental Studies & Toxicology

National
Research Council

500
5th Street, NW

Washington,
DC 20001

PH:
202-334-2347

FAX:
202-334-2752

E-mail:
emantus@nas.edu